natgillin/translations-raw huggingface dataset:
Medianen for progressionsfri overlevelse var 48,1 uger (95 % konfideninterval: 36,4; 62,1) hos de patienter, der fik behandling med lenalidomid/dexamethason, mens den var på 20,0 uger (95 % konfidensinterval: 16,1; 20,1) i placebo/dexamethason-patientgruppen.
The median progression free survival was 48.1 weeks (95% CI: 36.4, 62.1) in patients treated with lenalidomide/dexamethasone versus 20.0 weeks (95% CI: 16.1, 20.1) in patients treated with placebo/dexamethasone.
Medianen for tiden til progression for disse endpoints varierede fra at være 0,7 til 2,1 måneder længere for TMZ end for procarbazin (log rank p = < 0,01 til 0,03).
The median times to progression in these endpoints ranged from 0.7 to 2.1 months longer for TMZ than for procarbazine (log rank p = < 0.01 to 0.03).
Medianf (min; maks): alle patienter
Medianf (min, max): all patients
Medianopfølgning (uger)4
Median follow-up (wks)4
Medianopfølgning er baseret på behandlede patienter.
4 Median follow-up is based on patients treated.
Medianoverlevelse (måneder) (95 % CI)
Median survival (months) (95% CI)
Medianoverlevelse (uger) (95 % CI)
Median survival (weeks)
Medianoverlevelse, uger
Median overall survival, weeks
Medianoverlevelsen for patienter behandlet med topotecan + BSC var 25,9 uger (95 % C.I. 18,3; 31,6) sammenlignet med 13,9 uger (95 % C.I. 11,1; 18,6) for patienter, der fik BSC alene (p = 0,0104).
The median survival for patients treated with topotecan + BSC was 25.9 weeks (95 % C.I. 18.3, 31.6) compared to 13.9 weeks (95 % C.I. 11.1, 18.6) for patients receiving BSC alone (p = 0.0104).
Medianoverlevelsen for patienter behandlet med topotecan + BSC var 25,9 uger (95 % C.I. 18,3; 31,6) sammenlignet med 13,9 uger (95 % C.I. 11,1; 18,6) for patienter, der fik BSC alene (p = 0,0104).
The median survival for patients treated with topotecan + BSC was 25.9 weeks (95 % C.I. 18.3, 31.6) compared to 13.9 weeks (95 % C.I. 11.1, 18.6) for patients receiving BSC alone (p=0.0104).
Medianoverlevelsen for patienter behandlet med topotecan + BSC var 25,9 uger (95 % C.I. 18,3; 31,6) sammenlignet med 13,9 uger (95 % C.I. 11,1; 18,6) for patienter, der fik BSC alene (p = 0.0104).
The median survival for patients treated with topotecan + BSC was 25.9 weeks (95 % C.I. 18.3, 31.6) compared to 13.9 weeks (95 % C.I. 11.1, 18.6) for patients receiving BSC alone (p = 0.0104).
Medianoverlevelsen for patienter behandlet med topotecan + BSC var 25,9 uger (95 % C.I. 18,3; 31,6) sammenlignet med 13,9 uger (95 % C.I. 11,1; 18,6) for patienter, der fik BSC alene (p = 0.0104).
The median survival for patients treated with topotecan + BSC was 25.9 weeks (95 % C.I. 18.3, 31.6) compared to 13.9 weeks (95 % C.I. 11.1, 18.6) for patients receiving BSC alone (p=0.0104).
Medianoverlevelsen for patienter behandlet med topotecan + BSC var 25,9 uger (95 % C.I. 18,3; 31,6) sammenlignet med 13,9 uger (95 % C.I. 11,1; 18,6) for patienter, der fik BSC alene (p=0,0104).
The median survival for patients treated with topotecan + BSC was 25.9 weeks (95 % C.I. 18.3, 31.6) compared to 13.9 weeks (95 % C.I. 11.1, 18.6) for patients receiving BSC alone (p=0.0104).
Medianoverlevelsen for patienter behandlet med topotecan + BSC var 25,9 uger (95 % C.I. 18,3; 31,6) sammenlignet med 13,9 uger (95 % C.I. 11,1; 18,6) for patienter, der modtog BSC alene (p = 0,0104).
The median survival for patients treated with topotecan + BSC was 25.9 weeks (95 % C.I. 18.3, 31.6) compared to 13.9 weeks (95 % C.I. 11.1, 18.6) for patients receiving BSC alone (p = 0.0104).
Medianoverlevelsen for patienter behandlet med topotecan + BSC var 25,9 uger (95 % CI 18,3; 31,6) sammenlignet med 13,9 uger (95 % CI 11,1; 18,6) for patienter, der fik BSC alene (p = 0,0104).
The median survival for patients treated with topotecan + BSC was 25.9 weeks (95 % C.I. 18.3, 31.6) compared to 13.9 weeks (95 % C.I. 11.1, 18.6) for patients receiving BSC alone (p = 0.0104).
Medianoverlevelsen for patienter behandlet med topotecan + BSC var 25,9 uger (95 % CI: 18,3; 31,6) sammenlignet med 13,9 uger (95 % CI: 11,1; 18,6) for patienter, der fik BSC alene (p = 0,0104).
The median survival for patients treated with topotecan + BSC was 25.9 weeks (95 % C.I. 18.3, 31.6) compared to 13.9 weeks (95 % C.I. 11.1, 18.6) for patients receiving BSC alone (p=0.0104).
Medianoverlevelsen i B+M+P-behandlingsgruppen var 56,4 måneder sammenlignet med 43,1 i M+P-behandlingsgruppen.
Median survival for the B+M+P treatment group was 56.4 months compared to 43.1 for the M+P treatment group.
Medianoverlevelsen var 442 dage (docetaxel + capecitabin) vs.
Median survival was 442 days (docetaxel + capecitabine) vs.
Medianresponsvarigheda
Mediana response duration
Mediantid til begyndelse af symptomlindring alle symptomer (t):
Median time to onset of symptom relief: all symptoms (hours):
Mediantid til CR, måneder (område)
Median time to CR, months (range)
Mediantid til død var 40,8 måneder i placebo-gruppen og 56,5 måneder i Perjeta-gruppen (se tabel 2, figur 2).
The median time to death was 40.8 months in the placebo-treated group and 56.5 months in the Perjeta-treated group (see Table 2, Figure 2).
Mediantid til første forværring af WHO-funktionsstatus var signifikant længere i TPF-armen end i PF.
Median time to first deterioration of WHO performance status was significantly longer in the TPF arm compared to PF.
Mediantid til første respons, måneder (95 % CI)
Median time to First Response, months (95% CI)
Mediantid til første trombocytopeniske hændelse var 28 dage (interval: 1- 968 dage), og medianvarigheden pr. hændelse var 14 dage (interval: 1-666 dage).
Among patients with thrombocytopenia AEs, the median time to first event was 28 days (range, 1 to 968 days) and median duration per event was 14 days (range, 1 to 666 days).
Mediantid til hændelse (måneder)
Median time to event (months)
Mediantid til indledende respons, måneder (område)
Median time to initial response, months (range)
Mediantid til indtræden af disse endokrinopatier var 1,5 måneder (0,0- 10,1).
Median time to onset of these endocrinopathies was 1.5 months (range: 0.0-10.1).
Mediantid til indtræden af disse endokrinopatier var 2,8 måneder (0,4-14,0).
Median time to onset of these endocrinopathies was 2.8 months (range: 0.4-14.0).
Mediantid til indtræden var 0,5 måneder (0,0-9,7).
Median time to onset was 0.5 months (range: 0.0-9.7).
Mediantid til indtræden var 1,1 måneder (0,0-10,4).
Median time to onset was 1.1 months (range: 0.0-10.4).
Mediantid til indtræden var 1,4 måneder (0,0-11,0).
Median time to onset was 1.4 months (range: 0.0-11.0).
Mediantid til indtræden var 1,4 måneder (0,0-17,2).
Median time to onset was 1.4 months (range: 0.0- 17.2).
Mediantid til indtræden var 1,8 måneder (0,0-20,9).
Median time to onset was 1.8 months (range: 0.0- 20.9).
Mediantid til indtræden var 1,9 måneder (0,0-18,7).
Median time to onset was 1.9 months (range: 0.0-18.7).
Mediantid til indtræden var 2,3 måneder (0,7-6,7).
Median time to onset was 2.3 months (range: 0.7-6.7).
Mediantid til indtræden var 2,6 måneder (0,5-14,7).
Median time to onset was 2.6 months (range: 0.5-14.7).
Mediantid til MMR hos respondenter alene, ugerb; (95 % CI)
Median Time to MMR for responders only, weeksb, (95% CI)
Mediantid til nadir for neutropeni ≥ grad 3 er 23 dage (8-104) efter første ONIVYDE-dosis.
The median time to nadir for ≥ Grade 3 neutropenia is 23 (range 8-104) days post first dose of treatment with ONIVYDE.
Mediantid til næste CLL-behandling
Median time to next CLL therapy
Mediantid til objektivt respons,d måneder (95 % CI)
Median time to objective response,d months (95% CI)
Mediantid til progression
Median time to
Mediantid til recidiv (fornyet stigning af albuminkorrigeret serumcalcium ≥ 2,9 mmol/l) var 30-40 dage for patienter i behandling med zoledronsyre i forhold til 17 dage for patienter i behandling med 90 mg pamidronat (p-værdier: 0,001 for 4 mg og 0,007 for
Median time to relapse (re-increase of albumin-corrected serum calcium ≥ 2.9 mmol/l) was 30 to 40 days for patients treated with zoledronic acid versus 17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid).
Mediantid til recidiv (fornyet stigning af albuminkorrigeret serumcalcium 2,9 mmol/l) var 30–40 dage for patienter i behandling med zoledronsyre i forhold til 17 dage for patienter i behandling med 90 mg pamidronat (p-værdier: 0,001 for 4 mg og 0,007 for 8 mg zoledronsyre).
Median time to relapse (re-increase of albumin-corrected serum calcium 2.9 mmol/l) was 30 to 40 days for patients treated with zoledronic acid versus 17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid).
Mediantid til recidiv (stigning af albuminkorrigeret serum-calcium til niveauer over 3 mmol/l) var 18-19 dage for doser på 2 mg og 4 mg.
The median time to relapse (return of albumin-corrected serum calcium to levels above 3 mmol/l) was 18 - 19 days for the 2 mg and 4 mg doses.
Mediantid til respons
Median time to response
Mediantid til SRE (dage)
Median time to SRE
Mediantid til transfusionsuafhængighed (uger)
Median Time to Transfusion Independence (weeks)
Mediantid til viral suppression**
Median time to viral suppression
Mediantiden for PFS var 4,2 måneder (95% CI: 2,8, 5,7) for pemetrexed (HR = 0,59, p = 0,0004 for crizotinib sammenlignet med pemetrexed) og 2,6 måneder (95% CI: 1,6, 4,0) for docetaxel (HR = 0,30, p < 0,0001 for crizotinib sammenlignet med docetaxel).
The median PFS times were 4.2 months (95% CI: 2.8, 5.7) for pemetrexed (HR=0.59; p-value=0.0004 for crizotinib compared with pemetrexed) and 2.6 months (95% CI: 1.6, 4.0) for docetaxel (HR=0.30; p-value <0.0001 for crizotinib compared with docetaxel).
Mediantiden for PFS var 6,9 måneder (95% CI: 6,6-8,3) for pemetrexed/cisplatin (HR = 0,49; p <0,0001 for crizotinib sammenlignet med pemetrexed/cisplatin) og 7,0 måneder (95% CI: 5,9-8,3) for pemetrexed/carboplatin (HR = 0,45; p <0,0001 for crizotinib sammenlignet med pemetrexed/carboplatin).
Median PFS times were 6.9 months (95% CI: 6.6, 8.3) for pemetrexed/cisplatin (HR=0.49; p-value <0.0001 for crizotinib compared with pemetrexed/cisplatin) and 7.0 months (95% CI: 5.9, 8.3) for pemetrexed/carboplatin (HR=0.45; p-value <0.0001 for crizotinib compared with pemetrexed/carboplatin).
Mediantiden for progressionen af retinitis i de 2 studier (GS-93-106 og GS-93-105) var for behandlingsgruppen 120 dage hhv. ikke opnået, hvorimod mediantiden var 22 hhv.
The median times to retinitis progression in the two efficacy studies (GS-93-106 and GS-93-105), were 120 days and not reached for the treatment arms vs.
Mediantiden for tilbagefald (at albuminkorrigeret serum-calcium igen steg til over 3 mmol/l) var 18-19 dage for doserne 2 mg og 4 mg.
The median time to relapse (re-increase of serum albumin-corrected serum calcium above 3 mmol/l) was 18-19 days for the 2 mg and 4 mg doses.
Mediantiden for tilbagefald (stigning af serum albuminkorrigeret serum-calcium til over 3 mmol/l) var 18-19 dage for doserne 2 mg og 4 mg.
The median time to relapse (return of albumin-corrected serum calcium to levels above 3 mmol/l) was 18 - 19 days for the 2 mg and 4 mg doses.
Mediantiden for tilbagefald (tilbagevendende stigning af serum albuminkorrigeret serum-calcium til over 3 mmol/l) var 18-19 dage for doserne 2 mg og 4 mg.
The median time to relapse (re-increase of serum albumin corrected serum calcium above 3 mmol/l) was 18-19 days for the 2 mg and 4 mg doses.
Mediantiden for tilbagefald (tilbagevendende stigning af serum albuminkorrigeret serum-calcium til over 3 mmol/l) var 18-19 dage for doserne 2 mg og 4 mg.
The median time to relapse (re-increase of serum albumin-corrected serum calcium above 3 mmol/l) was 18- 19 days for the 2 mg and 4 mg doses.
Mediantiden for tilbagefald var 26 dage med en dosis på 6 mg.
The median time to relapse was 26 days with a dose of 6 mg.
Mediantiden fra behandlingsstart til indtræden af svære eller dødelige (Grad 2-5) hudbivirkninger var 3 uger (interval 0,9–16 uger).
The median time to onset of moderate to severe or fatal (Grade 2 to 5) skin adverse reactions was 3 weeks from start of treatment (range 0.9 to 16 weeks).
Mediantiden fra behandlingsstart til indtræden af svære eller dødelige (Grad 3 til 5) immunrelaterede gastrointestinale bivirkninger var 8 uger (interval 5 til 13 uger).
The median time to onset of severe or fatal (Grade 3 to 5) immune-related gastrointestinal reactions was 8 weeks (range 5 to 13 weeks) from the start of treatment.
Mediantiden fra diagnosticering til første dosis var 32 måneder i lenvatinib plus everolimus-armen, 33 måneder i lenvatinib-armen og 26 måneder i everolimus-armen.
The median time from diagnosis to first dose was 32 months in the lenvatinib plus everolimus-treatment arm, 33 months in the lenvatinib arm and 26 months in the everolimus arm.
Mediantiden fra initiering af blinatumomab til de neurologiske hændelsers indtræden var 9 dage.
The median time from initiation of blinatumomab to onset of a neurologic event was 9 days.
Mediantiden fra randomisering til første tilbagevenden af AF/AFL i dronedarongruppen var 116 dage, dvs.
The median time from randomised to first AF/AFL recurrence in the dronedarone group was 116 days, i.e.
Mediantiden indtil de neurologiske hændelser indtræden var 12 dage hos disse patienter.
The median time to onset of a neurologic event in these patients was 12 days.
Mediantiden indtil den første hændelses indtræden var 3 dage fra starten af behandling med BLINCYTO.
The median time to onset to the first event was 3 days from the start of BLINCYTO treatment initiation.
Mediantiden indtil det første symptom på dermatologisk reaktion var 10 dage, og mediantiden indtil afhjælpning efter den sidste dosis af Vectibix var 28 dage.
The median time to first symptom of dermatologic reaction was 10 days, and the median time to resolution after the last dose of Vectibix was 28 days.
Mediantiden indtil første skeletrelaterede hændelse var 16,7 måneder for patienter behandlet med enzalutamid og 13,3 måneder for patienter, som modtog placebo (HR = 0,688, 95 % KI: [0,566, 0,835]; p <0,0001).
The median time to first skeletal-related event was 16.7 months for patients treated with enzalutamide and 13.3 months for patients who received placebo (HR = 0.688, 95% CI: [0.566, 0.835]; p < 0.0001).
Mediantiden indtil indtræden af en neurologisk hændelse var 9 dage.
The median time to onset of neurologic event was 9 days.
Mediantiden indtil progression var 186 dage (docetaxel+ capecitabin) vs.
The median time to progression was 186 days (docetaxel + capecitabine) vs.
Mediantiden indtil respons var 3,1 måneder (95% CI 2,89; 3,65).
The median time to response was 3.1 months (95% CI 2.89, 3.65).
Mediantiden siden sidste dosis oralt jern(II) var 22 måneder i forsøgsgruppen og 17 måneder i placeboarmen.
The median time since last dose of OFP was 22 months in the experimental group and 17 months in the placebo arm.
Mediantiden til at nå maksimale plasmakoncentrationer forekommer mellem 1,5 og 3 timer efter doseringen, idet lav peroral biotilgængelighed (< 5 %) skyldes signifikant first-pass-metabolisme.
Median time to reach maximum plasma concentrations occurs between 1.5 to 3 hours after dosing, with low oral bioavailability (<5%) due to significant first-pass metabolism.
Mediantiden til debut var 4,4 måneder (0,0 til 12,7 måneder) i Cotellic-plus-vemurafenib-armen.
The median time to first onset was 4.4 months (range 0.0 to 12.7 months) in the Cotellic plus vemurafenib arm.
Mediantiden til den opstod var kortere hos patienter, som fik HD-Dex, sammenlignet med Pom + LD-Dex (1,3 uger versus 2,1 uger).
Median time to onset was earlier in patients who received HD-Dex compared with Pom + LD-Dex (1.3 weeks versus 2.1 weeks).
Mediantiden til første flare var længere i den sammenlagte gruppe, der fik belimumab, i forhold til den gruppe, der fik placebo (110 dage i forhold til 84 dage, hazard ratio = 0,84, p=0,012).
The median time to the first flare was delayed in the pooled group receiving belimumab compared to the group receiving placebo (110 vs 84 days, hazard ratio=0.84, p=0.012).
Mediantiden til første hændelse var 56 dage (interval: 2-840 dage), og medianvarigheden pr. hændelse var 14 dage (interval: 1-454 dage).
The median time to first event was 56 days (range, 2 to 840 days) and the median duration per event was 14 days (range, 1 to 454 days).
Mediantiden til første start i lenvatinib- gruppen var 11,1 uger.
The median time to first onset in lenvatinib-treated patients was 11.1 weeks.
Mediantiden til første symptom var 10,2 uger (alle grader) og 7,6 uger (grad ≥ 3) i lenvatinib plus everolimus- gruppen.
The median time to first onset of was 10.2 weeks (any grade) and 7.6 weeks (Grade ≥ 3) in the lenvatinib plus everolimus-treated group.
Mediantiden til indtræden af alvorlig neutropeni var dag 12 med en medianvarighed på 7 dage.
Median time to onset of severe neutropenia was Day 12 with a median duration of 7 days.
Mediantiden til indtræden af alvorlig neutropeni var nidage, og medianvarigheden syv dage.
Median time to onset of severe neutropenia was nine days and the median duration was seven days.
Mediantiden til indtræden af alvorlig trombocytopeni var dag 15 med en medianvarighed på 2,5 dage.
Median time to onset of severe thrombocytopenia was Day 15 with a median duration of 2.5 days.
Mediantiden til indtræden af diarré af grad 2 eller værre var 9 dage.
The median time to onset of grade 2 or worse diarrhoea was 9 days.
Mediantiden til indtræden af moderat til alvorlig anæmi var dag 12 med en medianvarighed på 7 dage.
Median time to onset of moderate to severe anaemia was Day 12 with a median duration of 7 days.
Mediantiden til initiering af cytotoksisk kemoterapi var 28,0 måneder for patienter, der fik enzalutamid, og 10,8 måneder for patienter, der fik placebo (HR = 0,350, 95 % KI: [0,303; 0,403], p < 0,0001).
The median time to initiation of cytotoxic chemotherapy was 28.0 months for patients receiving enzalutamide and 10.8 months for patients receiving placebo (HR = 0.350, 95% CI: [0.303, 0.403], p < 0.0001).
Mediantiden til komplet bedring var 22,4 uger hos patienter, som fik Pom + LD-Dex, og 13,6 uger hos patienter, som fik HD-Dex.
Median time to resolution was 22.4 weeks in patients who received Pom + LD-Dex and 13.6 weeks in patients who received HD-Dex.
Mediantiden til neuropatien opstod var 2,1 uge med en variation fra 0,1 til 48,3 uger.
Median time to onset of neuropathy was 2.1 weeks, varying from 0.1 to 48.3 weeks.
Mediantiden til opnåelse af det tilsigtede trombocyttal på ≥ 90.000 pr. µl (ENABLE 1) eller ≥ 100.000 pr. µl (ENABLE 2) var 2 uger.
The median time to achieve the target platelet count ≥ 90,000/µl (ENABLE 1) or ≥ 100,000/µl (ENABLE 2) was 2 weeks.
Mediantiden til PS ≥ 2 for Lonsurf-gruppen og placebogruppen var henholdsvis 5,7 måneder og 4,0 måneder med en hazard ratio på 0,66 (95% CI: [0,56, 0,78]), p < 0,0001.
The median time to PS ≥ 2 for the Lonsurf group and placebo group was 5.7 months and 4.0 months, respectively, with a hazard ratio of 0.66 (95% CI: [0.56, 0.78]), p < 0.0001.
Mediantiden til PSA-progression ifølge PCWG2-kriterier var 11,2 måneder for patienter behandlet med enzalutamid og 2,8 måneder for patienter, der fik placebo [HR = 0,169, (95 % KI: 0,147; 0,195), p < 0,0001].
The median time to PSA progression per PCWG2 criteria was 11.2 months for patients treated with enzalutamide and 2.8 months for patients who received placebo [HR = 0.169, (95% CI: 0.147, 0.195), p < 0.0001].
Mediantiden til recidiv var 26 dage ved en dosis på 6 mg.
The median time to relapse was 26 days with a dose of 6 mg.
Mediantiden til SEGA-progression, baseret på en central radiologisk gennemgang, blev ikke nået i nogen af behandlingsarmene.
Median time to SEGA progression based on central radiology review was not reached in either treatment arm.
Mediantiden til start i lenvatinib- gruppen var 16 dage.
The median time to onset in lenvatinib-treated patients was 16 days.
Mediantiden til transfusionsuafhængighed i armen med lenalidomid 10 mg var 4,6 uger.
The median time to transfusion independence in the lenalidomide 10 mg arm was 4.6 weeks.
Mediantiden til transfusionsuafhængighed var 4,1 uger.
The median time to transfusion independence was 4.1 weeks.
Mediantiden til trombocyttallet igen var over 50.000/mm3 var 14 dage.
The median time to recovery of platelet counts above 50,000/mm3 was 14 days.
Mediantiden til udvikling af neutropeni grad 3 eller 4 var 12 uger i de kliniske fase 3-studier med MF.
In the phase 3 clinical studies in MF, in patients who developed grade 3 or 4 neutropenia, the median time to onset was 12 weeks.
Mediantiden, før alle RAVer blev ikke-detekterbare, var 1,04 år for genotype 1b.
The median time for all RAVs to become undetectable was 1.04 years for genotype 1b.
Mediantiden, før alle RAVer blev ikke-detekterbare, var 1,11 år.
The median time for all RAVs to become undetectable was 1.11 years.
Mediantiderne, før de mest relevante boceprevir-resistente varianter set hos genotype 1a-patienter (>10 %) blev ikke-detekterbare, var følgende: R155K+V36M: 0,69 år; V36M: 0,89 år; R155K+T54S: 1,05 år; R155K: 1,08 år; og T54S:
The median times for the most relevant boceprevir-resistant variants observed in genotype 1a patients (> 10%) to become undetectable were as follows: R155K+V36M, 0.69 years; V36M, 0.89 years; R155K+T54S,
Mediantiderne, før de mest relevante boceprevir-resistente varianter set hos genotype 1b-patienter (>10 %) blev ikke- detekterbare, var følgende: I/V170A: 0,46 år; T54A: 0,47 år; V55A: 0,83 år; A156S: 0,89 år; og T54S: 1,11 år.
The median times for the most relevant boceprevir-resistant variants observed in genotype 1b patients (> 10%) to become undetectable were as follows: I/V170A, 0.46 years; T54A, 0.47 years; V55A, years; A156S, 0.89 years; and T54S, 1.11 years.
Mediantrombocyttallet ved udgangsniveauet var 16.000 pr. µl i begge behandlingsgrupper, og i eltrombopag-gruppen blev mediantrombocyttallet fastholdt over 50.000 pr. µl ved alle besøg fra dag 15; i modsætning hertil forblev mediantrombocyttallet i placebogruppen < 30.000 pr. µl gennem hele studiet.
Median platelet counts at baseline were 16,000/l for both treatment groups and in the eltrombopag group were maintained above 50,000/µl at all on-therapy visits starting at Day 15; in contrast, median platelet counts in the placebo group remained < 30,000/µl throughout the study.
Medianvarighed af behandlingen var 13 uger for VDDx-gruppen og 11 uger for BDx-gruppen.
The median duration of treatment was 13 weeks for the VDDx group and 11 weeks for the BDx group.
Medianvarighed af hændelse (måneder)
Median duration of event (months)
Medianvarighed af overlevelse (måneder)
Median duration of survival (months)
Medianvarighed af progressionsfri overlevelse (måneder)
Median duration of PFS (months)
Medianvarighed af respons
Median duration of response
Medianvarighed af respons på kemoterapi +/- strålebehandling (måneder) (95% CI)
Median duration of response to chemotherapy ± radiotherapy (months) (95% CI)
Medianvarighed dage (mdr.)
Median duration Days (months)
Medianvarigheden af en hændelse var 15 dage (interval 1-336 dage) for ALAT og 14 dage (interval på 1-595 dage) for ASAT.
The median duration of an event was 15 days (range, 1 to 336 days), and 14 days (range, 1 to 595 days) for ALT and AST, respectively.
Medianvarigheden af fuldstændigt TMA-respons, uger (interval)1
Median Duration of complete TMA response, weeks (range)1
Medianvarigheden af førstevalgsbehandling var henholdsvis 82 og 8 måneder i Glivec- og INF- armene syv år efter, at den sidste patient var rekrutteret.
Seven years after the last patient had been recruited, the median duration of first-line treatment was 82 and 8 months in the Glivec and IFN arms, respectively.
Medianvarigheden af førstevalgsbehandling var henholdsvis 82 og 8 måneder i imatinib- og INF- armene syv år efter, at den sidste patient var rekrutteret.
Seven years after the last patient had been recruited, the median duration of first-line treatment was 82 and 8 months in the imatinib and IFN arms, respectively.
Medianvarigheden af remission var 8,9 måneder, og median-RFS (recidivfri overlevelse) var 7,6 måneder.
The median duration of remission was 8.9 months, and the median relapse-free survival (RFS) was 7.6 months.